Key result
High-dose losartan slows annual eGFR loss to ~0.7 mL/min/year in IgA nephritis.
Why the study?
Previous studies reported varying results regarding the influence of the ACE gene on ACEI and ARB therapy, and the efficacy of high-dose ARB and its interaction with ACE gene polymorphism had not been explored.
RCT (n=226)
Open-label
Simple randomization via computer-generated random numbers in a 2:3:2:3 ratio
Yes
Answers are grounded in this paper and cite their sources.
High-dose losartan may slow eGFR loss in IgA nephritis; leaves open confirmation in larger trials before practice change.
Background/aims Several studies have reported varying results of the influence of ACE gene on ACEI/ARB therapy. The efficacy of high dose ARB and its influence on ACE gene have not been explored. This is a 6 year randomised trial in IgA nephritis comparing high dose ARB (Losartan 200 mg/day) with normal dose ARB (Losartan 100 mg/day), normal dose ACEI (20 mg/day) and low dose ACEI (10 mg/day). Results Patients on high dose ARB had significantly lower proteinuria, 1.0 +/- 0.8 gm/day compared to 1.7 +/- 1.0 g/day in the other groups (P = 0.0005). The loss in eGFR was 0.7 ml min(-1)year(-1) for high dose ARB compared to 3.2-3.5 ml min(-1)year(-1) for the other three groups (P = 0.0005). There were more patients on high dose ARB with improvement in eGFR compared to other three groups (P < 0.001). Comparing patients with the three ACE genotypes DD, ID and II, all three groups responded well to therapy with decrease in proteinuria (P < 0.002). Only those on low dose ACEI (10 mg/day) with the I allele had increased in ESRF (P = 0.037). Conclusion High dose ARB is more efficacious in reducing proteinuria and preserving renal function when compared with normal dose ARB and ACEI, and also obviates the genomic influence of ACE gene polymorphism on renal survival.
No takes yet. Share an insight, caveat, or question.
Woo et al. (2008) conducted an RCT in Biopsy-proven primary IgA nephritis (n=226). High-dose Losartan vs. Normal-dose Losartan (100 mg/day), normal-dose Enalapril (20 mg/day), and low-dose Enalapril (10 mg/day) was evaluated on Annual loss in estimated glomerular filtration rate (eGFR, mL/min/year) at 6 years (p=0.0005). High-dose losartan reduced annual eGFR loss to 0.7 mL/min/year compared with 3.2-3.5 mL/min/year in lower-dose ARB/ACEI groups in IgA nephritis.
Synapse has enriched 10 related papers. Consider them for comparative context: